Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Other Working Capital Changes (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Other Working Capital Changes data on record, last reported at $3.5 million in Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 128.87% year-over-year to $3.5 million; the TTM value through Dec 2025 reached $99000.0, up 1550.0%, while the annual FY2025 figure was $99000.0, 1550.0% up from the prior year.
  • Other Working Capital Changes reached $3.5 million in Q4 2025 per CCCC's latest filing, up from -$569000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $20.8 million in Q4 2022 and bottomed at -$26.2 million in Q4 2021.
  • Average Other Working Capital Changes over 5 years is -$1.3 million, with a median of -$43000.0 recorded in 2023.
  • The widest YoY moves for Other Working Capital Changes: up 23190.38% in 2024, down 28102.33% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at -$26.2 million in 2021, then surged by 179.35% to $20.8 million in 2022, then crashed by 100.21% to -$43000.0 in 2023, then tumbled by 28102.33% to -$12.1 million in 2024, then surged by 128.87% to $3.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were $3.5 million in Q4 2025, -$569000.0 in Q3 2025, and -$2.5 million in Q2 2025.